- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA ® (pembrolizumab) is MSD's anti-PD-1 therapy - The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy ...
LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback